FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068360815> ?p ?o ?g. }

• W2068360815 endingPage "1394" @default.
• W2068360815 startingPage "1391" @default.
• W2068360815 abstract "Future Medicinal ChemistryVol. 4, No. 11 CommentaryLab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?Rachel AirleyRachel AirleyDivision of Pharmacy & Pharmaceutical Sciences, School of Applied Sciences, University of Huddersfield, Huddersfield, West Yorkshire, UK. Search for more papers by this authorEmail the corresponding author at r.airley@hud.ac.ukPublished Online:2 Aug 2012https://doi.org/10.4155/fmc.12.81AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancerclinical trialscomparative oncologysynergytyrosine kinase inhibitorveterinaryReferences1 Martinez MN. Welcome to the animal pharmaceuticals special focus. Future Med. Chem.3(7),845–846 (2011).Link, CAS, Google Scholar2 Cardiff RD, Ward JM, Barthold SW. ‘One medicine – one pathology’: are veterinary and human pathology prepared?. Lab. Invest.88(1),18–26 (2008).Crossref, Medline, Google Scholar3 Paoloni M, Davis S, Lana S et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics10,625 (2009).Crossref, Medline, Google Scholar4 Breen M. Update on genomics in veterinary oncology. Top Companion Anim. Med.24(3),113–121 (2009).Crossref, Medline, Google Scholar5 Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest.18(8),781–792 (2000).Crossref, Medline, CAS, Google Scholar6 Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr. Cancer Drug Targets3(4),265–273 (2003).Crossref, Medline, CAS, Google Scholar7 Pinho SS, Carvalho S, Cabral J, Reis CA, Gärtner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl. Res.159(3),165–172 (2012).Crossref, Medline, Google Scholar8 Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Res.27(1A),155–164 (2007).Medline, CAS, Google Scholar9 Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr. Blood Cancer58(3),327–333 (2012).Crossref, Medline, Google Scholar10 Brown DC, Boston R, Coyne JC, Farrar JT. A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer. Pain Med.10(1),133–142 (2009).Crossref, Medline, Google Scholar11 Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I. Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo25(3),455–465 (2011).Medline, Google Scholar12 Klopfleisch R, Lenze D, Hummel M, Gruber AD. The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. Vet. J.190(2),236–243 (2011).Crossref, Medline, CAS, Google Scholar13 Vail DM, Michels GM, Khanna C et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) – a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet. Comp. Oncol.8(1),28–37 (2010).Crossref, Medline, CAS, Google Scholar14 Leblanc AK, Miller AN, Galyon GD et al. Preliminary evaluation of serial 18FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. Vet. Radiol. Ultrasound53(3),348–357 (2012).Medline, Google Scholar15 Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs63(5),513–522; discussion 523–524 (2003).Crossref, Medline, CAS, Google Scholar16 Postow MA, Carvajal RD. Therapeutic Implications of KIT in Melanoma. Cancer J.18(2),137–141 (2012).Crossref, Medline, CAS, Google Scholar17 London CA. Tyrosine kinase inhibitors in veterinary medicine. Top. Companion Anim. Med.24(3),106–112 (2009).Crossref, Medline, Google Scholar18 Misdorp W. Mast cells and canine mast cell tumours. A review. Vet. Q.26(4),156–169 (2004).Crossref, Medline, CAS, Google Scholar19 Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans. Am. Clin. Climatol. Assoc.116,185–203; discussion 203–204 (2005).Medline, Google Scholar20 Paoloni MC, Mazcko C, Fox E et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS ONE5(6),e11013 (2010).Crossref, Medline, Google Scholar21 London CA, Bear MD, McCleese J et al. Phase I evaluation of STA-1474, a prodrug of the novel Hsp90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS ONE6(11),e27018 (2011).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByDevelopment and verification of LEP 300 kilovoltage radiotherapy system for companion animals18 August 2022 | Journal of the Korean Physical Society, Vol. 81, No. 11β‑elemene enhances anticancer bone neoplasms efficacy of paclitaxel through regulation of GPR124 in bone neoplasms cells6 June 2018 | Oncology LettersTyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative reviewCritical Reviews in Oncology/Hematology, Vol. 88, No. 2 Vol. 4, No. 11 Follow us on social media for the latest updates Metrics Downloaded 311 times History Published online 2 August 2012 Published in print July 2012 Information© Future Science LtdKeywordscancerclinical trialscomparative oncologysynergytyrosine kinase inhibitorveterinaryFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2068360815 created "2016-06-24" @default.
• W2068360815 creator A5078975636 @default.
• W2068360815 date "2012-07-01" @default.
• W2068360815 modified "2023-09-23" @default.
• W2068360815 title "Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?" @default.
• W2068360815 cites W1977353582 @default.
• W2068360815 cites W2002828428 @default.
• W2068360815 cites W2004703923 @default.
• W2068360815 cites W2013713832 @default.
• W2068360815 cites W2014010217 @default.
• W2068360815 cites W2016576372 @default.
• W2068360815 cites W2037002623 @default.
• W2068360815 cites W2060959332 @default.
• W2068360815 cites W2085357061 @default.
• W2068360815 cites W2106179455 @default.
• W2068360815 cites W2108627173 @default.
• W2068360815 cites W2116507596 @default.
• W2068360815 cites W2116599555 @default.
• W2068360815 cites W2141590889 @default.
• W2068360815 cites W2146647803 @default.
• W2068360815 cites W2168030213 @default.
• W2068360815 cites W2315957672 @default.
• W2068360815 doi "https://doi.org/10.4155/fmc.12.81" @default.
• W2068360815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22857529" @default.
• W2068360815 hasPublicationYear "2012" @default.
• W2068360815 type Work @default.
• W2068360815 sameAs 2068360815 @default.
• W2068360815 citedByCount "4" @default.
• W2068360815 countsByYear W20683608152013 @default.
• W2068360815 countsByYear W20683608152016 @default.
• W2068360815 countsByYear W20683608152018 @default.
• W2068360815 countsByYear W20683608152022 @default.
• W2068360815 crossrefType "journal-article" @default.
• W2068360815 hasAuthorship W2068360815A5078975636 @default.
• W2068360815 hasBestOaLocation W20683608152 @default.
• W2068360815 hasConcept C104863432 @default.
• W2068360815 hasConcept C143998085 @default.
• W2068360815 hasConcept C161191863 @default.
• W2068360815 hasConcept C2779473830 @default.
• W2068360815 hasConcept C41008148 @default.
• W2068360815 hasConcept C512399662 @default.
• W2068360815 hasConcept C55493867 @default.
• W2068360815 hasConcept C71924100 @default.
• W2068360815 hasConcept C86803240 @default.
• W2068360815 hasConceptScore W2068360815C104863432 @default.
• W2068360815 hasConceptScore W2068360815C143998085 @default.
• W2068360815 hasConceptScore W2068360815C161191863 @default.
• W2068360815 hasConceptScore W2068360815C2779473830 @default.
• W2068360815 hasConceptScore W2068360815C41008148 @default.
• W2068360815 hasConceptScore W2068360815C512399662 @default.
• W2068360815 hasConceptScore W2068360815C55493867 @default.
• W2068360815 hasConceptScore W2068360815C71924100 @default.
• W2068360815 hasConceptScore W2068360815C86803240 @default.
• W2068360815 hasIssue "11" @default.
• W2068360815 hasLocation W20683608151 @default.
• W2068360815 hasLocation W20683608152 @default.
• W2068360815 hasLocation W20683608153 @default.
• W2068360815 hasOpenAccess W2068360815 @default.
• W2068360815 hasPrimaryLocation W20683608151 @default.
• W2068360815 hasRelatedWork W135528526 @default.
• W2068360815 hasRelatedWork W1546820302 @default.
• W2068360815 hasRelatedWork W1923367337 @default.
• W2068360815 hasRelatedWork W2552627378 @default.
• W2068360815 hasRelatedWork W2748952813 @default.
• W2068360815 hasRelatedWork W2897496508 @default.
• W2068360815 hasRelatedWork W2969083999 @default.
• W2068360815 hasRelatedWork W3186157739 @default.
• W2068360815 hasRelatedWork W2410740379 @default.
• W2068360815 hasRelatedWork W3112094302 @default.
• W2068360815 hasVolume "4" @default.
• W2068360815 isParatext "false" @default.
• W2068360815 isRetracted "false" @default.
• W2068360815 magId "2068360815" @default.
• W2068360815 workType "article" @default.